BlackRock’s Burning Rock Biotech BNR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$33 Hold
4
﹤0.01% 5647
2026
Q1
$65 Sell
4
-6
-60% -$157 ﹤0.01% 5624
2025
Q4
$202 Hold
10
﹤0.01% 5458
2025
Q3
$87 Hold
10
﹤0.01% 5407
2025
Q2
$32 Hold
10
﹤0.01% 5425
2025
Q1
$45 Buy
10
+4
+67% +$25 ﹤0.01% 5390
2024
Q4
$41 Hold
6
﹤0.01% 5363
2024
Q3
$20 Hold
6
﹤0.01% 5201
2024
Q2
$39 Sell
6
-1
-14% -$8 ﹤0.01% 5256
2024
Q1
$47 Hold
7
﹤0.01% 5263
2023
Q4
$60 Sell
7
-131
-95% -$1.21K ﹤0.01% 5340
2023
Q3
$1.34K Sell
138
-4,054
-97% -$63.3K ﹤0.01% 5315
2023
Q2
$90.1K Hold
4,192
﹤0.01% 4946
2023
Q1
$118K Sell
4,192
-1,015
-19% -$30.4K ﹤0.01% 4921
2022
Q4
$117K Sell
5,207
-150,599
-97% -$3.44M ﹤0.01% 4992
2022
Q3
$3.72M Sell
155,806
-7,146
-4% -$231K ﹤0.01% 3888
2022
Q2
$4.74M Buy
162,952
+19,277
+13% +$861K ﹤0.01% 3843
2022
Q1
$13.3M Buy
143,675
+14,053
+11% +$1.22M ﹤0.01% 3420
2021
Q4
$12.4M Sell
129,622
-54,301
-30% -$7.44M ﹤0.01% 3547
2021
Q3
$32.9M Buy
183,923
+10,392
+6% +$2.31M ﹤0.01% 2939
2021
Q2
$51.1M Buy
+173,531
New +$51.3M ﹤0.01% 2690

Other funds holding BNR

BlackRock's BNR Position: Q2 2026 in Review

BlackRock held its Burning Rock Biotech (BNR) position steady in Q2 2026 at 4 shares worth $33. The position accounts for ﹤0.01% of the portfolio, ranked #5647.

BlackRock first reported a position in BNR in Q2 2021 and has held it in 21 quarters since. The position peaked at $51.1M in Q2 2021. 3 funds tracked by Wall St. Rank hold BNR as of Q2 2026.

  • BlackRock held 4 shares of Burning Rock Biotech worth $33 as of Q2 2026.
  • BlackRock left its Burning Rock Biotech share count unchanged in Q2 2026.
  • Burning Rock Biotech made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5647 holding.
  • BlackRock first reported a position in Burning Rock Biotech in Q2 2021 and has held it in 21 quarters since.
  • BlackRock's Burning Rock Biotech position peaked at $51.1M in Q2 2021.
  • 3 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.